Table 1. Randomised trials evaluating EGFR-TKIs in EGFR-mutation positive patients with NSCLC.

Study/phase	Treatment arms	No. patients; region	RR (%); P	PFS (months)	HR; P	OS (months)	HR; P
IPASS/III (9,10)	Gefitinib vs. carboplatin-taxol	261; Asia	71.2 vs. 47.3; <0.001	9.5 vs. 6.3	0.48; <0.001	21.6 vs. 21.9	1; 0.990
First-SIGNAL/III (11)	Gefitinib vs. cisplatin-gemcitabine	96; Korea	84.6 vs. 37.5; 0.002	8.5 vs. 6.7	0.54; 0.086	27.2 vs. 25.6	1.043; 0.428
WJTOC 3405/III (12,13)	Gefitinib vs. cisplatin-docetaxel	177; Japan	62.1 vs. 32.2; <0.0001	9.2 vs. 6.3	0.488; <0.0001	36.0 vs. 39.0	1.19; 0.443
NEJ002/III (14,15)	Gefitinib vs. carboplatin-taxol	230; Japan	73.7 vs. 30.7; <0.001	10.4 vs. 5.4	0.30; <0.001	27.7 vs. 26.6	0.887; 0.483
OPTIMAL/III (16,17)	Erlotinib vs. carboplatin-gemcitabine	154; China	83.0 vs. 36.0; <0.0001	13.1 vs. 4.6	0.16; <0.0001	22.8 vs. 27.2	1.19; 0.2663
EURTAC/III (18)	Erlotinib vs. cisplatin-docetaxel	174; Europe	58.0 vs. 15.0; <0.0001	9.7 vs. 5.2	0.37; <0.0001	19.3 vs. 19.5	1.04; 0.87
ENSURE/III (19)	Erlotinib vs. cisplatin-gemcitabine	148; Asia	62.7 vs. 33.6; <0.0001	11.0 vs. 5.3	0.34; <0.0001	26.3 vs. 25.5	0.91; 0.607
LUX-LUNG 3/III (20,21)	Afatinib vs. cisplatin-pemetrexed	345; Global	56.0 vs s. 23.0; 0.001	11.1 vs. 6.9	0.58; 0.001	28.2 vs. 28.2	0.88; 0.39
LUX-LUNG 6/III (21,22)	Afatinib vs. cisplatin-gemcitabine	364; China	67.0 vs. 23.0; <0.0001	11.0 vs. 5.6	0.28; <0.001	23.1 vs. 23.5	0.93; 0.61
LUX-LUNG 7/II (23,24)	Afatinib vs. gefitinib	319; Global	70.0 vs. 56.0; 0.0083	11.0 vs. 10.9	0.73; <0.017	27.9 vs. 24.5	0.86; 0.258
JO25567/II (25)	Erlotinib + bevacizumab vs. erlotinib	154; Japan	69.3 vs. 63.6; 0.4951	16.0 vs. 9.7	0.54; 0.0015	NR	NR

EGFR-TKIs, epidermal growth factor receptor-tyrosine kinase inhibitors; HR, hazard ratio; NR, not reached; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; RR, response rate.